These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1063 related items for PubMed ID: 20649798

  • 1. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP, Lecluse LL, Driessen RJ, Spuls PI, Boezeman JB, van de Kerkhof PC, De Jong EM.
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [Abstract] [Full Text] [Related]

  • 2. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R.
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [Abstract] [Full Text] [Related]

  • 3. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
    Martyn-Simmons CL, Green L, Ash G, Groves RW, Smith CH, Barker JN.
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1394-7. PubMed ID: 19573024
    [Abstract] [Full Text] [Related]

  • 4. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD.
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [Abstract] [Full Text] [Related]

  • 5. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
    Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM.
    Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
    [Abstract] [Full Text] [Related]

  • 6. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B, Sánchez-Carazo JL, Pérez-Ferriols A, Laguna C, Oliver V, Alegre V.
    Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
    [Abstract] [Full Text] [Related]

  • 7. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ, van de Kerkhof PC, de Jong EM.
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [Abstract] [Full Text] [Related]

  • 8. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG, Kircik L, Callis Duffin K, Pariser D, Hooper M, Wenkert D, Thompson EH, Yang J, Kricorian G, Koo J.
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [Abstract] [Full Text] [Related]

  • 9. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A, Esposito M, Costanzo A, Chimenti S.
    Am J Clin Dermatol; 2009 Nov; 10(5):319-24. PubMed ID: 19658444
    [Abstract] [Full Text] [Related]

  • 11. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA.
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M, Perricone R, Chimenti S, Chimenti MS.
    Dermatology; 2012 Apr; 225(4):312-9. PubMed ID: 23295383
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A, ACCEPT Study Group.
    N Engl J Med; 2010 Jan 14; 362(2):118-28. PubMed ID: 20071701
    [Abstract] [Full Text] [Related]

  • 17. Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab.
    van Lümig PP, Driessen RJ, Roelofs-Thijssen MA, Boezeman JB, van de Kerkhof PC, de Jong EM.
    Br J Dermatol; 2011 Aug 14; 165(2):375-82. PubMed ID: 21428975
    [Abstract] [Full Text] [Related]

  • 18. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB.
    J Drugs Dermatol; 2013 Aug 14; 12(8):874-80. PubMed ID: 23986160
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study.
    Papp K, Ho V, Teixeira HD, Guerette B, Chen K, Lynde C.
    J Eur Acad Dermatol Venereol; 2012 Aug 14; 26(8):1007-13. PubMed ID: 22023702
    [Abstract] [Full Text] [Related]

  • 20. Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.
    Hoffmann JH, Knoop C, Enk AH, Hadaschik EN.
    J Dermatol Sci; 2014 Dec 14; 76(3):180-5. PubMed ID: 25306295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.